Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) has scheduled a board meeting for Monday, 31 August 2026. The agenda includes:

1. Reviewing and approving the interim financial results of Leads Biolabs and its subsidiaries for the six months ended 30 June 2026. 2. Considering a recommendation on the payment of an interim dividend, if any.

The meeting will be chaired by Dr. Kang Xiaoqiang, who serves concurrently as Chairman, Executive Director and Chief Executive Officer. The Board currently comprises nine directors: three executive directors (Dr. Kang Xiaoqiang, Dr. Lai Shoupeng, Mr. Zuo Honggang), three non-executive directors (Mr. Zhang Yincheng, Dr. Chen Renhai, Dr. Wu Fenglan) and three independent non-executive directors (Dr. Zhang Hongbing, Mr. Du Yilong, Ms. Du Jiliu).

The announcement underscores the company’s adherence to scheduled financial disclosures and governance practices ahead of publishing its interim results.